TREM-1 inhibitor specificity and timing of treatment initiation can impact its therapeutic efficacy in cancer and inflammatory disease
These findings for the first time demonstrate that both inhibitor specificity and timing of treatment initiation are crucial for therapeutic TREM-1 inhibition. This has significant implications for clinical strategies targeting TREM-1, particularly informing tailored treatment approaches for cancer and inflammatory diseases.
Authors
- Alexander B. Sigalov (ORCID: https://orcid.org/0000-0003-2118-1800)
Institutions
- SignaBlok (United States) (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fonc.2025.1689771
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Eye Institute
- National Cancer Institute
- National Institute of General Medical Sciences
- National Institute of Arthritis and Musculoskeletal and Skin Diseases